​
​

OmniAb (OABI) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChartTranscripts

OmniAb Revenue Highlights

Latest Revenue (Y)

$34.16M

Latest Revenue (Q)

$4.17M

Main Segment (Y)

Service

OmniAb Revenue by Period

OmniAb Revenue by Year

DateRevenueChange
2023-12-31$34.16M-42.17%
2022-12-31$59.08M70.02%
2021-12-31$34.75M49.34%
2020-12-31$23.27M27.02%
2019-12-31$18.32M-

OmniAb generated $34.16M in revenue during NA 2023, up -42.17% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

OmniAb Revenue by Quarter

DateRevenueChange
2024-09-30$4.17M-45.21%
2024-06-30$7.61M100.32%
2024-03-31$3.80M-21.17%
2023-12-31$4.82M-11.96%
2023-09-30$5.48M-21.15%
2023-06-30$6.95M-58.95%
2023-03-31$16.92M-52.13%
2022-12-31$35.34M411.51%
2022-09-30$6.91M-4.01%
2022-06-30$7.20M-25.19%
2022-03-31$9.62M-55.36%
2021-12-31$21.56M243.43%
2021-09-30$6.28M12.39%
2021-06-30$5.58M-15.32%
2021-03-31$6.60M-50.51%
2020-12-31$13.33M167.25%
2020-09-30$4.99M-

OmniAb generated $4.17M in revenue during Q3 2024, up -45.21% compared to the previous quarter, and up 60.06% compared to the same period a year ago.

OmniAb Revenue Breakdown

OmniAb Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23
Service$12.18M
Royalty$1.28M

OmniAb's latest annual revenue breakdown by segment (product or service), as of Dec 23: Service (90.46%), and Royalty (9.54%).

Quarterly Revenue by Product

Product/ServiceSep 24Dec 23Sep 23
Royalty$318.00K$834.00K$451.00K
Service$2.48M$9.16M$3.02M

OmniAb's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Service (88.63%), and Royalty (11.37%).

OmniAb Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
LEGNLegend Biotech$285.14M$93.99M
OABIOmniAb$34.16M$4.17M
IDYAIDEAYA Biosciences$23.39M-
ITOSiTeos Therapeutics$12.60M$35.00M
IKNAIkena Oncology$9.16M-
IPSCCentury Therapeutics$2.23M$791.00K
KROSKeros Therapeutics$151.00K$37.00K
CGEMCullinan Oncology--
BCABBioAtla-$11.00M
NGMNGM Biopharmaceuticals-$165.00K
VRNAVerona Pharma-$5.62M
TALSTourmaline Bio--
OLMAOlema Pharmaceuticals--
ACETAdicet Bio--
ERASErasca--
PASGPassage Bio--
PMVPPMV Pharmaceuticals--
VORVor Biopharma--
GLUEMonte Rosa Therapeutics-$4.70M
EWTXEdgewise Therapeutics--

OABI Revenue FAQ

What is OmniAb’s yearly revenue?

OmniAb's yearly revenue for 2023 was $34.16M, representing a decrease of -42.17% compared to 2022. The company's yearly revenue for 2022 was $59.08M, representing an increase of 70.02% compared to 2021. OABI's yearly revenue for 2021 was $34.75M, representing an increase of 49.34% compared to 2020.

What is OmniAb’s quarterly revenue?

OmniAb's quarterly revenue for Q3 2024 was $4.17M, a -45.21% decrease from the previous quarter (Q2 2024), and a -23.83% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $7.61M, a 100.32% increase from the previous quarter (Q1 2024), and a 9.62% increase year-over-year (Q2 2023). OABI's quarterly revenue for Q1 2024 was $3.8M, a -21.17% decrease from the previous quarter (Q4 2023), and a -77.53% decrease year-over-year (Q1 2023).

What is OmniAb’s revenue growth rate?

OmniAb's revenue growth rate for the last 3 years (2021-2023) was -1.68%, and for the last 5 years (2019-2023) was 86.51%.

What are OmniAb’s revenue streams?

OmniAb's revenue streams in c 23 are Service, and Royalty. Service generated $12.18M in revenue, accounting 90.46% of the company's total revenue Royalty generated $1.28M in revenue, accounting 9.54% of the company's total revenue

What is OmniAb’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of OmniAb was Service. This segment made a revenue of $12.18M, representing 90.46% of the company's total revenue.